Step Therapy's Balancing Act - Protecting Patients while Addressing High Drug Prices.
作者信息
Sachs Rachel E, Kyle Michael Anne
机构信息
From Washington University School of Law, St. Louis (R.E.S.); and Harvard Medical School, Boston (M.A.K.).
出版信息
N Engl J Med. 2022 Mar 10;386(10):901-904. doi: 10.1056/NEJMp2117582. Epub 2022 Mar 5.
Abstract
摘要
相似文献
1
Step Therapy's Balancing Act - Protecting Patients while Addressing High Drug Prices.阶梯治疗的平衡之举——在应对高昂药价的同时保护患者。
N Engl J Med. 2022 Mar 10;386(10):901-904. doi: 10.1056/NEJMp2117582. Epub 2022 Mar 5.
2
Aetna Health, Inc. v. Davila: Implications for public health policy.安泰健康保险公司诉达维拉案：对公共卫生政策的影响。
Public Health Rep. 2004 Sep-Oct;119(5):510-2. doi: 10.1016/j.phr.2004.07.009.
3
Recent developments in health insurance, life insurance, and disability insurance case law.
Tort Insur Law J. 2002 Winter;37(2):471-520.
4
The Kassebaum-Kennedy bill--the limits of incrementalism.卡斯鲍姆-肯尼迪法案——渐进主义的局限性。
N Engl J Med. 1997 Jul 3;337(1):64-7. doi: 10.1056/NEJM199707033370123.
5
Recent developments in employee benefits law.
Tort Trial Insur Pract Law J. 2005 Winter;40(2):345-68.
6
Recent developments in health insurance, life insurance, and disability insurance case law.
Tort Trial Insur Pract Law J. 2005 Winter;40(2):485-520.
7
Contracts: Sixth Circuit interprets COB clause to hold ERISA insurer liable.
J Law Med Ethics. 1997 Winter;25(4):321-2.
8
The public-private dynamics of national immunization policy.
Am J Prev Med. 2000 Oct;19(3 Suppl):19-20. doi: 10.1016/s0749-3797(00)00214-2.
9
Recent developments in health insurance, life insurance, and disability insurance case law.
Tort Trial Insur Pract Law J. 2006 Winter;41(2):469-510.
10
Recent developments in health insurance and life insurance case law.
Tort Insur Law J. 1998 Winter;33(2):489-527.
引用本文的文献
1
Supply Chain Volatility of Repackaged Intravitreal Bevacizumab: A Survey of the American Society of Retina Specialists.再包装玻璃体内注射贝伐单抗的供应链波动：美国视网膜专家协会的一项调查
J Vitreoretin Dis. 2025 Jul 8:24741264251352889. doi: 10.1177/24741264251352889.
2
The complexity of pharmaceutical expenditures across U.S. states.美国各州药品支出的复杂性。
Sci Rep. 2025 May 20;15(1):17541. doi: 10.1038/s41598-025-01885-4.
3
National perspectives of barriers by insurance and pharmacy benefit managers in pediatric inflammatory bowel disease.保险和药品福利管理人员对儿童炎症性肠病治疗障碍的全国性观点。
JPGN Rep. 2025 Feb 10;6(2):80-90. doi: 10.1002/jpr3.70004. eCollection 2025 May.
4
The Impact of Step Therapy on Individuals with Psoriatic Disease in the USA: Patient and Provider Perspectives.阶梯治疗对美国银屑病患者的影响：患者及医疗服务提供者的观点
Dermatol Ther (Heidelb). 2025 May 3. doi: 10.1007/s13555-025-01430-1.
5
Bevacizumab First in DRCR Protocol AC vs Real-World Physician Treatment Choice for Diabetic Macular Edema: Two-Year Cost Analysis.贝伐单抗在糖尿病性黄斑水肿的糖尿病视网膜病变临床研究网络（DRCR）方案A与现实世界中医生治疗选择中的应用：两年成本分析
J Vitreoretin Dis. 2024 Sep 14:24741264241275283. doi: 10.1177/24741264241275283.
6
Analyzing the Benefits and Costs of the Safe Step Act on Patients, Physicians, and Insurers.分析《安全步骤法案》对患者、医生和保险公司的收益与成本。
J Psoriasis Psoriatic Arthritis. 2024 Jul;9(3):115-120. doi: 10.1177/24755303241253203. Epub 2024 May 7.
7
Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40.患有糖尿病性黄斑水肿且视力<20/40 的眼睛转为使用阿柏西普时符合转换标准的风险因素。
Ophthalmology. 2024 Aug;131(8):967-974. doi: 10.1016/j.ophtha.2024.01.037. Epub 2024 Feb 8.
8
Justification for initiating patiromer when restricted by prior authorization and clinical guidance in a US health care system.在美国医疗体系中，出于事先授权和临床指南的限制，启动帕替洛默尔治疗的理由。
J Manag Care Spec Pharm. 2022 Dec;28(12):1410-1418. doi: 10.18553/jmcp.2022.28.12.1410.
9
Evidence for Step Therapy in Diabetic Macular Edema.糖尿病性黄斑水肿阶梯治疗的证据。
N Engl J Med. 2022 Aug 25;387(8):751-752. doi: 10.1056/NEJMe2208454. Epub 2022 Jul 14.
10
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.阿柏西普单药治疗或贝伐单抗一线治疗糖尿病性黄斑水肿。
N Engl J Med. 2022 Aug 25;387(8):692-703. doi: 10.1056/NEJMoa2204225. Epub 2022 Jul 14.
本文引用的文献
1
Variation In Use And Content Of Prescription Drug Step Therapy Protocols, Within And Across Health Plans.处方药物分步治疗方案在医疗计划内和跨医疗计划使用和内容的变化。
Health Aff (Millwood). 2021 Nov;40(11):1749-1757. doi: 10.1377/hlthaff.2021.00822.
2
Do patients benefit from legislation regulating step therapy?患者是否从控制阶梯疗法的立法中受益？
Health Econ Policy Law. 2022 Jul;17(3):282-297. doi: 10.1017/S1744133121000153. Epub 2021 Apr 12.
3
The ethics of 'fail first': guidelines and practical scenarios for step therapy coverage policies.“先失败”的伦理：阶梯式治疗覆盖政策的指南和实际情况。
Health Aff (Millwood). 2014 Oct;33(10):1779-85. doi: 10.1377/hlthaff.2014.0516.
Zotero 插件